TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Pomerantz Llp
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

Pomerantz LLP is investigating potential securities fraud claims against Corcept Therapeutics following the FDA's issuance of a Complete Response Letter for its relacorilant drug on December 31, 2025. Despite the company's pivotal GRACE trial meeting its primary endpoint, the FDA requested additional effectiveness evidence. The announcement triggered a 50.42% stock price decline, falling from $70.20 to $34.80 per share.

Insights
CORT   negative

The company received an FDA Complete Response Letter denying approval for its lead drug candidate relacorilant, resulting in a severe 50.42% stock price decline. Additionally, securities fraud investigations have been initiated against the company and its officers/directors, indicating potential investor harm and regulatory setbacks.